Lipfendra (Enlicitide): The First PCSK9 Inhibitor You Can Take as a Pill

A patient sat across from me last month frustrated. He’s on a strong statin, he’s added ezetimibe, and his LDL is still hanging in the low 100s when I want it under 70 for someone with his history. I brought up a PCSK9 inhibitor, one of the most powerful cholesterol drugs we have, and he stopped me at one word. Injection. He didn’t want a shot, not every two weeks, not every month, not at all. For years that was the end of the conversation. As of this morning, it isn’t. The FDA approved Lipfendra, a PCSK9 inhibitor you swallow once a day like any other pill.

This is a real change in how we lower cholesterol. PCSK9 inhibitors have been some of the most effective medicines we’ve ever had for driving LDL down, and until now the only way to get one into your body was through a needle. A tablet removes that barrier for a lot of people. Let me walk through what Lipfendra is, how it works, how far it lowers your LDL, how it stacks up against the injectable drugs, and the practical things worth knowing before you start, including one dosing quirk you have to get right.

What Lipfendra Is

Lipfendra, scientific name enlicitide, is a once-daily prescription pill that lowers LDL cholesterol by blocking a protein called PCSK9. It’s the first oral drug in a class that until now existed only as an injection.

Your LDL cholesterol, the kind that builds plaque in your arteries, gets cleared from your blood by your liver. PCSK9 is a protein that works against that clearance and lets LDL climb. The PCSK9 inhibitors block it, and the result is a large drop in LDL. Three of these drugs already exist, and they’ve done a lot of good. Two are antibodies you inject at home every two to four weeks, evolocumab and alirocumab, sold as Repatha and Praluent. One is a different kind of drug, inclisiran, sold as Leqvio, given as a shot in the office twice a year. Lipfendra reaches the same target as all of them. The difference is that it’s a small molecule engineered to survive your stomach and get absorbed, so it can be taken as a tablet.

That sounds like a small distinction. In practice it’s a large one. Swallowing a pill is the most ordinary thing in the world for anyone who already takes a morning medication, and a good number of my patients who needed this level of cholesterol lowering balked when the only option was a needle.

How It Works

Lipfendra binds to PCSK9 and holds it out of action. With PCSK9 blocked, your liver keeps more of the receptors it uses to clear LDL, so it pulls more cholesterol out of your blood and your LDL number falls.

Let me explain the machinery, because it’s worth seeing. The surface of your liver cells is studded with tiny units called LDL receptors. Think of them as garbage disposals. They grab LDL particles out of your bloodstream and grind them away. The more of these disposals you have running, the lower your LDL stays. PCSK9 is a protein that jams that system. When PCSK9 latches onto one of these receptors, the whole unit gets dragged inside the cell and destroyed instead of being sent back to the surface to work again. More PCSK9 activity means fewer working disposals, which means less cholesterol cleared and a higher LDL.

Lipfendra steps in and neutralizes PCSK9. It’s a specially built molecule that clamps onto the protein and keeps it from reaching your LDL receptors. With PCSK9 out of the way, those receptors survive, they recycle back to the surface, and they get back to the job they were made for. Your liver starts clearing LDL from your blood the way it’s supposed to. This is the same mechanism as the injectable antibodies. The drug simply lets your body do its own work.

We know this target is the right one from human genetics. A small number of people are born making very little active PCSK9. They run low LDL their whole lives and rarely have heart attacks. Their arteries stay clean for decades. The PCSK9 inhibitors are our way of giving everyone else a version of that protection.

How Much It Lowers Your LDL

In its main trial, Lipfendra lowered LDL cholesterol by about 57% compared to placebo. In people with inherited high cholesterol it lowered LDL by about 58%. When it was tested head-to-head against other oral cholesterol pills, it lowered LDL by about 65%, far more than any of them.

Those numbers put Lipfendra in the top tier of cholesterol drugs. In the CORALreef Lipids trial, which enrolled roughly 2,900 adults, one 20 mg tablet a day dropped LDL by 57% at 24 weeks against placebo, and the effect held steady through a full year. That’s the kind of reduction that takes a patient sitting at an LDL of 140 down into the 50s or 60s, a range we’re glad to see in someone at high risk.

The drug did the same work for people who need it most. In a separate trial of adults with heterozygous familial hypercholesterolemia, an inherited condition that drives LDL very high from a young age, Lipfendra lowered LDL by about 58% at 24 weeks. More telling, 67% of those patients reached both a halving of their LDL and a level under 55, compared to 1% of the people on placebo. For a group that has fought stubborn numbers their entire lives, that’s a striking result.

There was also a direct comparison against the other pills we already use. In that trial, Lipfendra lowered LDL by about 65%, next to about 28% for ezetimibe, about 6% for bempedoic acid, and about 37% for the two combined. It wasn’t a close contest. Lipfendra also lowered the other markers we track, dropping non-HDL cholesterol and apolipoprotein B by roughly half, and reducing lipoprotein(a) as well. Those reductions look very much like what the injectable antibodies deliver.

How It Compares to the Injectable PCSK9 Drugs

Lipfendra’s LDL lowering, around 55 to 65%, sits right alongside the injectable antibodies Repatha and Praluent, and a step ahead of the twice-yearly injection Leqvio, which lowers LDL closer to 50%. The headline difference is the pill.

If you line these drugs up by how far they push LDL down, they cluster close together. Repatha lowers LDL by roughly 60% at full dose. Praluent lands in a similar range, depending on the dose. Leqvio, which works by a different mechanism, comes in a bit lower, around 50%. Lipfendra fits in among the antibodies rather than below them. A network analysis of these agents found the practical gaps between them are small once each is at its proper dose.

Where the drugs truly differ is delivery, and that’s where Lipfendra stands apart. Repatha and Praluent are self-injected every two to four weeks. Leqvio is a shot in the office twice a year, which suits people who’d rather not manage anything at home. Lipfendra is a daily tablet. None of these is better for everyone. Some patients love the set-it-and-forget-it rhythm of a twice-yearly injection. Others would much rather take a pill each morning and never think about needles. Having a real oral option in the class means I can match the drug to how a person actually wants to take their medicine, which is often what determines whether they stick with it.

One gap is worth naming. Repatha and Praluent have large trials proving they cut actual heart attacks and strokes. Lipfendra doesn’t have that outcome data yet. I’ll come back to that.

Dosing and the One Rule You Can’t Skip

The dose is one 20 mg tablet each morning on an empty stomach. Take it with water only, and don’t eat or drink anything else for 30 minutes after. That fasting step isn’t a suggestion. The pill needs an empty stomach to absorb properly.

This is the practical detail I’d sit and make sure a patient understood before writing the prescription. Getting a large molecule like this to survive the gut and get into the bloodstream took some clever formulation. The tablet includes an ingredient that helps it cross the intestinal wall, and that whole system only works on an empty stomach. Eat too soon and you blunt the absorption, which means you blunt the drug. So the routine is simple but firm. Take it first thing, with a glass of water, then give it a half hour before breakfast or coffee.

Beyond that, it’s an easy drug to live with. There’s no dose titration and no adjusting the amount based on how high your cholesterol runs. Your other medications can be taken on their own schedules. Lipfendra is cleared by your kidneys rather than processed heavily by your liver, which tends to keep it out of the way of the drug interactions that tangle up so many medications. In the trials, nearly everyone was also taking a statin, and many were on ezetimibe too, with no sign of trouble from the combination. Lipfendra is built to layer on top of the cholesterol treatment you’re already on.

Side Effects and Safety

Across its trials, Lipfendra’s side effects ran about the same as a placebo. Very few people stopped taking it. There was no signal of liver injury, no muscle problems, and no meaningful effect on blood sugar, kidney function, or other lab values.

I can be reassuring here, and I don’t say that lightly about a brand-new drug. In the year-long familial hypercholesterolemia trial, people stopped the medicine because of side effects at a rate of 2%, next to 3% on placebo. Serious problems occurred in about 4 to 5% of people in both groups, and none were judged to be caused by the drug. No one on Lipfendra developed the kind of liver injury we watch for, defined by liver enzymes and bilirubin rising together on blood tests. Blood counts, kidney function, liver tests, ECG readings, and long-term blood sugar all stayed steady, with no difference from placebo worth noting. New or worsening diabetes showed up in 2% on the drug and 3% on placebo, so there’s no diabetes signal.

That’s a clean early profile. It lines up with what we’d expect from the mechanism, since blocking PCSK9 with the injectable drugs has also proven very well tolerated over years of use. As with any medicine in its first year on the market, we’ll keep watching as more people take it for longer, and that’s true of every new drug, not a specific worry about this one.

Who Should and Shouldn’t Take It

Lipfendra fits people who need strong LDL lowering and either can’t get there on a statin plus ezetimibe, can’t tolerate statins, or carry inherited high cholesterol. It wasn’t studied in people with active liver disease, uncontrolled blood pressure or diabetes, or very high triglycerides, and it hasn’t been tested in pregnancy.

The clearest candidates are the patients I described at the start. You’re on a statin, maybe with ezetimibe added, you’ve been faithful about it, and your LDL is still above where your risk says it should be. Lipfendra can close that gap the way an injectable PCSK9 inhibitor would, without the needle. It’s also a strong option for people who genuinely can’t take statins after a careful trial, and for families carrying familial hypercholesterolemia who’ve battled high numbers since their twenties.

On the cautions, the trials excluded certain groups, and until the full prescribing details are settled those exclusions are the best guide to where care is warranted. People with active liver disease, uncontrolled hypertension or diabetes, and triglycerides at or above 400 weren’t enrolled. People with reduced kidney function were included and studied, which is useful to know given that the drug clears through the kidneys, though the data in severe kidney impairment are still limited. Pregnancy and breastfeeding weren’t studied, so this isn’t a drug to start if you’re pregnant, trying to become pregnant, or nursing. And as with any medication, a known allergy to it rules it out. Your own doctor will weigh these against the rest of your health before starting you.

The One Thing We’re Still Waiting On

Lipfendra is proven to lower LDL, and lowering LDL is one of the best-established ways to prevent heart attacks. The specific trial showing that Lipfendra itself cuts heart attacks and strokes is still running. It’s expected to finish in 2029.

I want to be clear-eyed about this, because it’s the honest limit on what we can say today. Decades of research have shown that when you lower LDL, you lower cardiovascular risk, and the deeper you drive it, the more events you prevent. Lipfendra lowers LDL as much as drugs we know reduce heart attacks. That’s a strong reason to expect it will do the same. Expectation isn’t proof, though. The injectable antibodies earned their place partly by proving in huge trials that they reduced actual events, and Lipfendra’s version of that trial, called CORALreef Outcomes, won’t report until 2029. For most patients the LDL lowering is reason enough to use it. For anyone who wants the fullest possible evidence before committing, that pending trial is a fair thing to weigh.

Where It Fits in the Bigger Picture

Lipfendra adds a genuinely new tool to cholesterol care, an oral drug with injection-level power. It doesn’t replace statins, which stay the foundation. It gives us a pill for people who need more than a statin and ezetimibe can provide.

The way I lower cholesterol is a ladder. We start with lifestyle and a statin, which does the heavy lifting and has the deepest evidence behind it. If LDL is still too high, we add ezetimibe, a gentle second pill. When that isn’t enough, we reach for the strong agents, the PCSK9 inhibitors and the twice-yearly injection Leqvio. Until today, climbing to that top rung meant accepting an injection. Lipfendra puts a tablet on that rung for the first time. For someone with coronary artery disease who needs LDL under 55 and doesn’t want a shot, that’s a real gift.

I’ve spent my career telling patients that cholesterol is one of the most controllable risks we have for the heart. Every few years a tool comes along that makes that promise easier to keep. A once-a-day pill that switches off a protein working against your arteries is one of the bigger ones. If your LDL has been stubborn and an injection wasn’t for you, this is worth a conversation.

Frequently Asked Questions

How much will Lipfendra lower my cholesterol?

In its main trial, Lipfendra lowered LDL by about 57% compared to placebo, and by about 58% in people with inherited high cholesterol. Tested against other cholesterol pills, it lowered LDL about 65%. For most people that’s enough to reach their LDL goal, even when a statin alone hasn’t gotten them there.

How is Lipfendra different from Repatha, Praluent, and Leqvio?

They all block PCSK9 and lower LDL by similar amounts. The difference is how you take them. Repatha and Praluent are injections every two to four weeks, and Leqvio is a shot in the office twice a year. Lipfendra is the first one that comes as a daily pill.

How do I take it?

One 20 mg tablet each morning on an empty stomach, with water only, and nothing else to eat or drink for 30 minutes after. That fasting step is required, because the pill needs an empty stomach to absorb properly. Take it first thing, then wait a half hour before breakfast.

What are the side effects?

In the trials, side effects were about the same as a placebo, and very few people stopped the drug. There was no liver injury, no muscle problems, and no effect on blood sugar or kidney function worth noting. It’s an early but reassuring safety picture.

Is Lipfendra proven to prevent heart attacks?

Not yet directly. It’s proven to lower LDL a lot, and lowering LDL is one of the best-established ways to prevent heart attacks. The specific trial testing whether Lipfendra itself reduces heart attacks and strokes is still running and is expected to finish in 2029.

Can I take it with my statin?

Yes. Lipfendra is designed to be added on top of a statin, and most people in the trials were taking one, many with ezetimibe as well, with no trouble from the combination. It layers onto the cholesterol treatment you’re already on.

Talk With Us About Your Cholesterol

If your LDL has stayed above goal on a statin, or a statin hasn’t suited you and you’ve wanted strong cholesterol lowering without an injection, Lipfendra is a new option worth discussing, and it’s an easy conversation to have.

If you have questions about your cholesterol or want help thinking through your treatment choices, our office is glad to help. To get in touch, visit our practice website. For coordinated cardiovascular care, we work with the team at San Diego Cardiovascular Associates. For the wider picture of how we lower cholesterol, see my guides to LDL cholesterol, PCSK9 inhibitors, Leqvio (inclisiran), and ezetimibe.

Getting cholesterol right is one of the highest-value things we do in cardiology, and the plan is always tailored to your risk and how you tolerate each medicine. If you’d like that sorted in person, I see patients in Encinitas and from across San Diego.

References

1. Navar, Ann Marie, Elena Mikhailova, Alberico L. Catapano, et al. "A Placebo-Controlled Trial of the Oral PCSK9 Inhibitor Enlicitide." New England Journal of Medicine (2026).

2. Ballantyne, Christie M., Laura Gellis, Jean-Claude Tardif, et al. "Efficacy and Safety of Oral PCSK9 Inhibitor Enlicitide in Adults With Heterozygous Familial Hypercholesterolemia." Journal of the American Medical Association (2026).

3. Catapano, Alberico L., Elena Mikhailova, Ann Marie Navar, et al. "Oral PCSK9 Inhibitor Enlicitide Versus Oral Nonstatin Therapies: A Phase 3 Randomized Clinical Trial." Journal of the American College of Cardiology (2026).

4. Hurwitz, Madelyn, Anjali Kulkarni, Francoise A. Marvel, and Jaideep Patel. "A Comprehensive Review of PCSK9 Inhibitor Therapy." Journal of Cardiovascular Pharmacology (2026).

5. Burnett, John R., and Amanda J. Hooper. "MK-0616: An Oral PCSK9 Inhibitor for Hypercholesterolemia Treatment." Expert Opinion on Investigational Drugs (2023).

6. Nurmohamed, Nick S., Ann Marie Navar, and John J. P. Kastelein. "New and Emerging Therapies for Reduction of LDL-Cholesterol and Apolipoprotein B: JACC Focus Seminar 1/4." Journal of the American College of Cardiology 77, no. 12 (2021): 1564-1575.

7. American Diabetes Association Professional Practice Committee. "Cardiovascular Disease and Risk Management: Standards of Care in Diabetes-2026." Diabetes Care (2026).

8. Ahmad, Zahid, Anandita Agarwala, Marina Cuchel, et al. "Update on Familial Hypercholesterolemia: An Expert Clinical Consensus From the National Lipid Association." Journal of Clinical Lipidology (2026).

Published on damianrasch.com. The above information was composed by Dr. Damian Rasch, drawing on individual insight and bolstered by digital research and writing assistance. The information is for educational purposes only and does not constitute medical advice.